NDV-vectored Lyme disease vaccines


Principal Investigator: Siba K Samal
Abstract: DESCRIPTION (provided by applicant): We propose to evaluate the use of the Newcastle disease virus (NDV) as a delivery vector for host immunization with borrelial antigens as vaccine targets. We will assess protection of NDV-immunized rodent hosts against Borrelia burgdorferi infection, known as Lyme disease or Lyme borreliosis. NDV is an avian virus that is highly immunogenic yet attenuated in mammals including primates. NDV is a safe vaccine vector for human use and anti-NDV antibodies are readily induced in human, as shown in clinical trial studies. Infectious NDV can be easily produced from transfected cDNAs by reverse genetics, a method that has been instrumental for studying basic biology and pathogenesis of the virus. In recent years, these technologies are also adopted for studies with translational goals, such as engineering NDV vectors against variety of animal and human diseases. In this proposal, we will assess if NDV-derived vectors could be an additional approach for host immunization against B. burgdorferi infection and identify protective efficacy of several newly characterized novel spirochete antigens. Our current data show that even a single immunization of rodents with recombinant NDV elicits a robust antibody response against tested borrelial antigens. We will initiate additional series of immunization studies with NDV constructs carrying several new target antigens, assess antibody development in rodent hosts and finally determine if specific antibodies in the host interfere with spirochete infectivity. If more than one antigen is promising we will combine multiple antigens in search of an additive effect. We will also perform studies for understanding the mechanism of humoral and cellular immune responses associated with host protection. Overall, these studies will contribute to the development of preventive measures against multi-organ infection caused by B. burgdorferi.
Funding Period: 2013-02-01 - 2015-01-31
more information: NIH RePORT

Detail Information

Research Grants30

  1. Pacific NorthWest Regional Center of Excellence (PNWRCE)
    Jay A Nelson; Fiscal Year: 2013
    ..pseudomallei host pathogen response during both the septicemic as well as the intracellular phases of the disease. ..
  2. Rocky Mountain Regional Center of Excellence or Biodefense and Emerging Infectiou
    John T Belisle; Fiscal Year: 2013
    ..abstract_text> ..
  3. Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery
    Dennis R Burton; Fiscal Year: 2013
    ..The team will be sustained by five Scientific Research Support Components (SRSCs), including strong Operations and Management, that have been assembled to maximally accelerate progress toward the designated goals. ..
  4. Oklahoma Center for Respiratory and Infectious Diseases
    Lin Liu; Fiscal Year: 2013
    ..The completion of the goals of the present COBRE will have a major impact on research programs on respiratory infectious diseases in the State of Oklahoma. ..
  5. Southeast Regional Centers of Excellence for Biodefense &Emerging Infectious Di
    Philip Frederick Sparling; Fiscal Year: 2013
    ..SERCEB brings new investigators to the biodefense effort through a combination of educational programs, support of innovative new projects, and the synergistic interactions among its world-class investigators. ..
  6. New England Regional Center of Excellence in Biodefense and Emerging Infectious D
    Dennis L Kasper; Fiscal Year: 2013
    ..NERCE will also continue its Developmental Projects program and Career Development in Biodefense program in an effort to initiate new research efforts and to attract new investigators to this field. ..
  7. Northeast Biodefense Center
    W Ian Lipkin; Fiscal Year: 2013
    ..As a Center based in a School of Public Health and a State Department of Health, the NBC has a firm commitment to and practical understanding of Emergency Preparedness. ..
  8. Center for the Study of Innate Immunity to HCV Infection
    Michael J Gale; Fiscal Year: 2013
    ..Our studies are linked with the U19 Clinical Core, and Projects 2 and 3 to feature translational approaches aimed at defining the virus-host interface that controls hepatic innate immunity and HCV infection. ..
  9. Pacific Southwest RCE for Biodefense &Emerging Infectious Diseases Research
    Alan G Barbour; Fiscal Year: 2013
    ..abstract_text> ..
  10. Optimizing HIV immunogen-BCR interactions for vaccine development
    LEONIDAS A STAMATATOS; Fiscal Year: 2013
    Rafi Ahmed; Fiscal Year: 2013
  12. Structure and Immunogenicity of Cleaved, Stabilized HIV-1 Envelope Trimers
    John P Moore; Fiscal Year: 2013
    ..Sunil Ahuja). Our shared goal is to overcome key structural and immunological challenges to developing a successful Env-based HIV-1 vaccine. ..
  13. Novel Ad/MVA and Ad/Protein HIV-1 Vaccines
    Dan H Barouch; Fiscal Year: 2013
    ..To define the mechanism of blocking acquisition of stringent SIV challenges by conducting antigen formulation and adoptive transfer studies in rhesus monkeys. ..
  14. Oxidation in Inflammation and Cardiovascular Disease
    Stanley L Hazen; Fiscal Year: 2013
    ..It may also lead to important insights for atherosclerosis risk assessment, diagnosis and therapy. ..